Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Bosch on the HPV Vaccination in the Prevention of Cervical Cancer

November 8th 2017

Xavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, introduces a second-generation vaccination against the human papilloma virus (HPV) for the prevention of cervical cancer.

Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer

November 7th 2017

A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer.

Dr. Mahantshetty Discusses Results of Chemoradiation in Cervical Cancer

November 7th 2017

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Dr. Zamarin on the Role of Pembrolizumab in Endometrial Cancer

November 7th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of pembrolizumab (Keytruda) for patients with endometrial cancer.

Pembrolizumab Demonstrates Safety and Efficacy in Cervical Cancer

November 4th 2017

In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.

FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer

October 27th 2017

The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.

Expert Discusses Immunotherapy Across Gynecologic Malignancies

October 24th 2017

Dmitriy Zamarin, MD, PhD, discusses the role of immunotherapy for patients with gynecologic malignancies.

Neoadjuvant Chemo Linked to Above 95% OS in Squamous Cell Cervical Cancer

October 23rd 2017

Investigators sought to assess the efficacy of adjuvant surgery after concurrent chemoradiotherapy in patients with bulky squamous cell carcinoma of the uterine cervix

Hydrocortisone Reduces Hypersensitivity Reactions in Women With Gynecologic Cancers

October 13th 2017

Adding IV hydrocortisone to standard dexamethasone prophylaxis reduced the incidence of hypersensitivity reactions in women undergoing paclitaxel-based treatment for gynecologic cancers

Dr. Zamarin on the Future Treatment Landscape of Gynecologic Malignancies

October 13th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies

October 13th 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.

Dr. Zamarin on the Role of Vaccines in Cervical Cancer

October 3rd 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of vaccines for patients with cervical cancer.

Dr. Ginsburg on Genetic Testing Guidelines for Gynecologic Malignancies

October 3rd 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses genetic testing for patients with gynecologic cancers.

Adjuvant CRT Linked to 83% Reduced Risk of Death in Endometrial Cancer

September 22nd 2017

Women with node-positive stage IIIC endometrial cancer assigned to adjuvant chemoradiation therapy had better survival than those assigned to chemotherapy or radiation therapy alone.

Dose-Dense Adjuvant Chemotherapy Shows Potential in Endometrial Cancer

September 22nd 2017

Dose-dense chemotherapy could be a superior option for adjuvant treatment of endometrial cancer compared with standard chemotherapy.

More Studies Needed to Improve Detection and Classification of Fallopian Tube Tumors

September 22nd 2017

Giampero (John) A. Martignetti, MD, PhD, explains that more large-size clinical trials need to be conducted to answer some of the burgeoning questions in the fallopian tube and ovarian cancer landscape.

Dr. Leitao Discusses Surgery in Gynecologic Malignancies

September 20th 2017

Mario M. Leitao, Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses surgery in gynecologic malignancies.

Dr. Zamarin on Lenvatinib Plus Pembrolizumab in Endometrial Cancer

September 20th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

Dr. Levine on Immunotherapy for Endometrial Cancer

September 19th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer

September 19th 2017

John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.